David McNinch

David McNinch has served as Chief Commercial Officer at Taysha Gene Therapies since 2025.

David is an accomplished biopharmaceutical leader with over 25 years of experience in corporate strategy, business development, strategic market development and global commercialization across multiple therapeutic areas. Before joining Taysha, David served as Chief Business Officer at Encoded Therapeutics, where he led corporate development, partnering and commercial strategy across the company’s gene therapy portfolio. Before Encoded, David served as Chief Commercial Officer at Prothena Corporation, where he led the development of the global commercial strategy for the organization’s immunotherapy pipeline. Prior to Prothena, he served as Senior Vice President of Commercial Operations at InterMune, where he led the design, build and operations of the organization’s commercial function through the successful launch of Esbriet, the first treatment for idiopathic pulmonary fibrosis. He subsequently supported the acquisition and integration of the company by Roche. David has also held various leadership roles of increasing responsibility within the commercial function at Ipsen, Genentech, Novartis and AstraZeneca.

David earned a B.S. in marketing and business administration from the Darla Moore School of Business at the University of South Carolina.